- Market Size (2026)
- USD 6.0 Bn
- Forecast (2036)
- USD 11.1 Bn
- CAGR (2026 to 2036)
- 6.3%
Pleural Diseases Therapeutics Market Forecast and Outlook By FMI
Summary of the Pleural Diseases Therapeutics Market
- Demand and Growth Drivers
- Chemotherapy and immunotherapy regimens for malignant pleural mesothelioma and pleural effusion are sustaining pharmaceutical procurement demand across hospital oncology and pulmonology departments.
- Procedural interventions including thoracentesis, pleurodesis, indwelling pleural catheters, and VATS are creating medical device and consumable demand at hospitals and ambulatory surgical centers.
- Immuno-oncology adoption for mesothelioma treatment, including checkpoint inhibitor combinations, is creating a high-value treatment segment that is shifting revenue composition toward biologic therapies.
- Product and Segment View
- Chemotherapy is expected to hold 58.2% of the Treatment segment in 2026.
- Injectable is expected to hold 49.0% of the Route Of Administration segment in 2026.
- Conventional Therapies is expected to hold 52.0% of the Technology segment in 2026.
- Geography and Competitive Outlook
- USA is expected to lead growth at 6.4%, supported by the largest oncology pharmaceutical market and mesothelioma treatment infrastructure.
- South Korea follows at 6.4%, driven by oncology treatment investment and clinical research participation.
- AstraZeneca plc and established players compete on oncology pipeline and device portfolio.
- Analyst Opinion
- The Pleural Diseases Therapeutics Market is evolving as new technologies and treatment approaches expand beyond established product categories.
- Regulatory developments and reimbursement frameworks are shaping adoption patterns and competitive dynamics across key markets.
- Companies that combine oncology pipeline with device portfolio are expected to gain procurement share over the forecast period.
- Emerging technologies and pipeline developments are creating opportunities for both established players and new market entrants.
Key Takeaways
- The Pleural Diseases Therapeutics Market was valued at USD 5.65 billion in 2025.
- By 2036, the Pleural Diseases Therapeutics Market is expected to be worth USD 11.06 billion.
- From 2026 to 2036, the market is projected to expand at a CAGR of 6.3%.
- The market is projected to create an incremental opportunity of USD 5.06 billion between 2026 and 2036.
- In 2026, Chemotherapy is expected to account for 58.2% of the Treatment segment, driven by the clinical burden of malignant pleural effusion and mesothelioma requiring chemotherapy, immunotherapy, and procedural interventions.
- USA (6.4%) and South Korea (6.4%) are two of the fastest growing markets in the world.
Pleural Diseases Therapeutics Market Definition
The Pleural Diseases Therapeutics Market covers pharmaceutical therapies (chemotherapy, immunotherapy, antibiotics, analgesics), surgical procedures (VATS, pleurodesis, thoracentesis), and medical devices (pleural catheters, drainage systems) for the treatment of malignant and non-malignant pleural conditions.
Pleural Diseases Therapeutics Market Inclusions
Market scope covers all commercially available products and services categorized by treatment (Treatment, Chemotherapy, Drug Class, Bullectomy, Video-Assisted Thoracoscopic Surgery, PleurX Catheter, Pleurodesis Therapy, Radiation Therapy, Thoracentesis, Thoracostomy), route of administration (Route Of Administration, Injectable, Oral, Intrapleural), technology (Technology, Conventional Therapies, Targeted Therapies), disease indication (Disease Indication, Malignant Pleural Diseases, Non Malignant Pleural Diseases), end users (End Users, Hospitals, Specialty Clinics, Others), distribution channel (Distribution Channel, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies). Revenue coverage spans the 2026 to 2036 forecast period.
Pleural Diseases Therapeutics Market Exclusions
The scope does not include general pulmonology products not indicated for pleural diseases, lung cancer treatments without pleural involvement, or respiratory diagnostic equipment sold separately.
Pleural Diseases Therapeutics Market Research Methodology
- Primary Research: FMI analysts conducted interviews with industry stakeholders and procurement decision-makers across key markets.
- Desk Research: Combined data from regulatory filings, industry publications, clinical and trade databases, and manufacturer disclosures.
- Market sizing and forecasting: Bottom-up aggregation across segments and regions, with adoption velocity modeling and cross-validation against industry benchmarks.
- Data validation: Cross-checked quarterly against industry production data, regulatory databases, and manufacturer disclosures.
Why is the Pleural Diseases Therapeutics Market Growing?
- Chemotherapy accounts for 58.2% of the treatment segment, reflecting the first-line role of systemic and combination chemotherapy in malignant pleural disease management.
- Malignant pleural diseases hold 61.0% of the disease indication segment, with pleural effusion and mesothelioma representing the primary treatment-intensive conditions.
- USA leads growth at 6.4%, supported by the largest oncology pharmaceutical market and mesothelioma treatment infrastructure.
The Pleural Diseases Therapeutics Market is growing as treatment options expand for malignant and non-malignant pleural conditions. Chemotherapy holds 58.2% of the treatment segment, with drug classes (antibiotics, antifungals, corticosteroids, analgesics, NSAIDs), surgical procedures, and device-based interventions contributing the treatment mix. Injectable administration leads at 49.0%, reflecting the intravenous and intrapleural delivery requirements of chemotherapy and biologic agents.
Conventional therapies account for 52.0% of the technology segment, with targeted biologics and immuno-oncology therapies representing the growth segment. Malignant pleural diseases hold 61.0%, with pleurisy, pneumothorax, and other non-malignant conditions contributing additional treatment demand. Hospitals represent 64.9% of end-user demand.
Hospital pharmacies hold 44.5% of distribution, with retail and online pharmacies serving outpatient maintenance therapy prescriptions. The market is shaped by the multidisciplinary nature of pleural disease management, requiring coordination across pulmonology, oncology, thoracic surgery, and interventional radiology departments.
Market Segmentation Analysis
- Chemotherapy holds 58.2% of the Treatment segment in 2026.
- Injectable accounts for 49.0% of the Route Of Administration segment.
The Pleural Diseases Therapeutics Market is organized across 6 segmentation dimensions: Treatment, Route Of Administration, Technology, Disease Indication, End Users, Distribution Channel.
Insights into the Chemotherapy Treatment Segment
In 2026, Chemotherapy is expected to account for 58.2% of the Treatment segment. Key sub-categories include Systemic Chemotherapy, Combination Chemotherapy.
Chemotherapy holds 58.2% of the segment, contributing to segment diversity.
Insights into the Conventional Therapies Technology Segment
In 2026, Conventional Therapies is expected to account for 52.0% of the Technology segment. Key sub-categories include Pharmacological Therapy, Surgical Procedures.
Conventional Therapies holds 52.0% of the segment, contributing to segment diversity.
Pleural Diseases Therapeutics Market Drivers, Restraints, and Opportunities
- Mesothelioma treatment combines systemic chemotherapy (pemetrexed/cisplatin), surgical debulking, and radiation therapy.
- Malignant pleural effusion requires repeated drainage procedures, pleurodesis, or indwelling pleural catheter placement.
- Checkpoint inhibitor combinations approved for mesothelioma first-line treatment are shifting prescribing patterns from chemotherapy-only regimens toward immunotherapy combinations.
The Pleural Diseases Therapeutics Market is shaped by clinical demand, technology development, regulatory frameworks, and access dynamics. Growth reflects the balance between demand drivers and adoption constraints.
Malignant Pleural Mesothelioma Treatment
Mesothelioma treatment combines systemic chemotherapy (pemetrexed/cisplatin), surgical debulking, and radiation therapy. Checkpoint inhibitor approvals (nivolumab/ipilimumab) have expanded the treatment toolkit and created a high-value biologic therapy segment.
Pleural Effusion Management
Malignant pleural effusion requires repeated drainage procedures, pleurodesis, or indwelling pleural catheter placement. These procedural interventions create recurring device and consumable demand at hospitals and ambulatory surgical centers.
Immuno-oncology Adoption
Checkpoint inhibitor combinations approved for mesothelioma first-line treatment are shifting prescribing patterns from chemotherapy-only regimens toward immunotherapy combinations. This creates higher per-patient treatment costs and shifts revenue toward biologic products.
Diagnostic and Staging Advances
Improved pleural biopsy techniques, biomarker testing, and imaging advances are enabling earlier and more accurate diagnosis of malignant pleural conditions. Earlier diagnosis creates opportunities for curative-intent treatment and expands the treated patient population.
Analysis of Pleural Diseases Therapeutics Market By Key Countries
.webp "Top Country Growth Comparison Pleural Diseases Therapeutics Market Cagr (2026 2036)")
| Country | CAGR |
|---|---|
| USA | 6.4% |
| UK | 6.2% |
| Japan | 6.3% |
| EU | 6.3% |
| South Korea | 6.4% |
- USA at 6.4% is supported by the largest oncology pharmaceutical market and mesothelioma treatment infrastructure.
- South Korea at 6.4% is supported by oncology treatment investment and clinical research participation.
- Japan at 6.3% is supported by advanced thoracic surgery infrastructure and aging population demographics.
- EU at 6.3% is supported by harmonized oncology treatment frameworks and clinical trial activity.
The global Pleural Diseases Therapeutics Market is projected to expand at a CAGR of 6.3% from 2026 to 2036. The analysis covers more than 30 countries.
Demand Outlook for Pleural Diseases Therapeutics Market in the United States
The United States is projected to grow at 6.4% through 2036. The largest oncology pharmaceutical market and mesothelioma treatment infrastructure are the primary factors shaping demand.
- The largest oncology pharmaceutical market and mesothelioma treatment infrastructure supports demand growth.
- Expanding demand base contributes to market expansion.
- Regulatory and institutional frameworks support market development.
Future Outlook for Pleural Diseases Therapeutics Market in the United Kingdom
The United Kingdom is projected to grow at 6.2% through 2036. NHS cancer treatment pathways and mesothelioma specialist centers are the primary factors shaping demand.
- NHS cancer treatment pathways and mesothelioma specialist centers supports demand growth.
- Expanding demand base contributes to market expansion.
- Regulatory and institutional frameworks support market development.
Opportunity Analysis of Pleural Diseases Therapeutics Market in Japan
Japan is projected to grow at 6.3% through 2036. Advanced thoracic surgery infrastructure and aging population demographics are the primary factors shaping demand.
- Advanced thoracic surgery infrastructure and aging population demographics supports demand growth.
- Expanding demand base contributes to market expansion.
- Regulatory and institutional frameworks support market development.
In-depth Analysis of Pleural Diseases Therapeutics Market in the European Union
The European Union is projected to grow at 6.3% through 2036. Harmonized oncology treatment frameworks and clinical trial activity are the primary factors shaping demand.
- Harmonized oncology treatment frameworks and clinical trial activity supports demand growth.
- Expanding demand base contributes to market expansion.
- Regulatory and institutional frameworks support market development.
Sales Analysis of Pleural Diseases Therapeutics Market in South Korea
South Korea is projected to grow at 6.4% through 2036. Oncology treatment investment and clinical research participation are the primary factors shaping demand.
- Oncology treatment investment and clinical research participation supports demand growth.
- Expanding demand base contributes to market expansion.
- Regulatory and institutional frameworks support market development.
Competitive Landscape and Strategic Positioning
- AstraZeneca plc holds a leading position based on oncology pipeline and device portfolio.
- Established players compete on oncology pipeline, device portfolio, specialist distribution, geographic footprint.
- Emerging players are focusing on specialized capabilities and niche market positioning.
AstraZeneca plc holds a leading position through its oncology pipeline and device portfolio. Bristol-Myers Squibb maintains a strong position through complementary capabilities.
Becton, Dickinson and Company, Roche Holding AG (Genentech), Rocket Medical plc compete on specialized capabilities and Geographic Footprint. These companies serve distinct market segments through targeted strategies.
Market entry requires investment in oncology pipeline, regulatory compliance, and distribution infrastructure. Established companies benefit from customer relationships and track records.
Key Companies in the Pleural Diseases Therapeutics Market
Key global companies leading the Pleural Diseases Therapeutics Market include:
- AstraZeneca plc, Bristol-Myers Squibb, Becton, Dickinson and Company, Roche Holding AG (Genentech) are the established market leaders with broad capabilities across oncology pipeline and device portfolio.
- Rocket Medical plc, Novocure, Smiths Medical have built regional positions through specialized capabilities.
- Veracyte, Inc., Medtronic, BioInvent International are entering through niche specialization and technology-driven differentiation.
Competitive Benchmarking: Pleural Diseases Therapeutics Market
| Company | Oncology Pipeline | Device Portfolio | Specialist Distribution | Geographic Footprint |
|---|---|---|---|---|
| AstraZeneca plc | High | High | Strong | Global |
| Bristol-Myers Squibb | High | High | Strong | Global |
| Becton, Dickinson and Company | High | High | Strong | Global |
| Roche Holding AG (Genentech) | Medium | High | Moderate | Regional |
| Rocket Medical plc | Medium | High | Moderate | Regional |
| Novocure | Medium | High | Moderate | Regional |
| Smiths Medical | Medium | Medium | Low | Regional |
| Veracyte, Inc. | Medium | Medium | Low | Regional |
| Medtronic | Medium | Medium | Low | Regional |
| BioInvent International | Medium | Medium | Low | Regional |
Source: Future Market Insights competitive analysis, 2026.
Key Developments in Pleural Diseases Therapeutics Market
- In 2025, AstraZeneca plc advanced its oncology pipeline through late-stage clinical developments and strategic investments.
- In 2025, Bristol-Myers Squibb focused on strengthening its oncology portfolio through clinical research and product pipeline expansion.
Key Players in the Pleural Diseases Therapeutics Market:
Major Global Players:
- AstraZeneca plc
- Bristol-Myers Squibb
- Becton, Dickinson and Company
- Roche Holding AG (Genentech)
- Rocket Medical plc
- Novocure
- Smiths Medical
Emerging Players/Startups
- Veracyte, Inc.
- Medtronic
- BioInvent International
Report Scope and Coverage
| Parameter | Details |
|---|---|
| Quantitative Units | USD 6.00 billion to USD 11.06 billion, at a CAGR of 6.3% |
| Market Definition | The Pleural Diseases Therapeutics Market covers pharmaceutical therapies (chemotherapy, immunotherapy, antibiotics, analgesics), surgical procedures (VATS, pleurodesis, thoracentesis), and medical devices (pleural catheters, drainage systems) for the treatment of malignant and non-malignant pleural conditions. |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa |
| Countries Covered | USA, UK, Japan, EU, South Korea, Italy, South Korea, 30 plus countries |
| Key Companies Profiled | AstraZeneca plc, Bristol-Myers Squibb, Becton, Dickinson and Company, Roche Holding AG (Genentech), Rocket Medical plc, Novocure, Smiths Medical, Veracyte, Inc., Medtronic, BioInvent International |
| Forecast Period | 2026 to 2036 |
| Approach | Hybrid bottom-up and top-down methodology starting with verified data, projecting adoption velocity across segments and regions. |
Market Segmentation Analysis
Pleural Diseases Therapeutics Market Market Segmented by Treatment:
- Chemotherapy
- Systemic Chemotherapy
- Combination Chemotherapy
- Drug Class
- Antibiotics
- Antifungals
- Corticosteroids
- Narcotic Analgesics
- Nonsteroidal Anti-Inflammatory Drugs
- Bullectomy
- Surgical Lung Volume Reduction
- Video-Assisted Thoracoscopic Surgery
- Minimally Invasive Thoracic Surgery
- PleurX Catheter
- Indwelling Pleural Catheter
- Pleurodesis Therapy
- Chemical Pleurodesis
- Radiation Therapy
- External Beam Radiation
- Thoracentesis
- Fluid Drainage Procedure
- Thoracostomy
- Chest Tube Placement
Pleural Diseases Therapeutics Market Market Segmented by Route Of Administration:
- Injectable
- Intravenous Administration
- Subcutaneous Injection
- Oral
- Tablets and Capsules
- Intrapleural
- Direct Pleural Administration
Pleural Diseases Therapeutics Market Market Segmented by Technology:
- Conventional Therapies
- Pharmacological Therapy
- Surgical Procedures
- Targeted Therapies
- Biologics
- Immuno Oncology Therapies
Pleural Diseases Therapeutics Market Market Segmented by Disease Indication:
- Malignant Pleural Diseases
- Pleural Effusion
- Mesothelioma
- Non Malignant Pleural Diseases
- Pleurisy
- Pneumothorax
Pleural Diseases Therapeutics Market Market Segmented by End Users:
- Hospitals
- Inpatient Care
- Surgical Units
- Specialty Clinics
- Pulmonology Clinics
- Others
Pleural Diseases Therapeutics Market Market Segmented by Distribution Channel:
- Hospital Pharmacies
- Inpatient Pharmacy Services
- Outpatient Pharmacy Services
- Retail Pharmacies
- Chain Pharmacies
- Online Pharmacies
- E-Commerce Platforms
Pleural Diseases Therapeutics Market Market by Region:
- North America
- USA
- Canada
- Mexico
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Western Europe
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- East Asia
- China
- Japan
- South Korea
- South Asia and Pacific
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- Middle East & Africa
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
Research Sources and Bibliography
- National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines: Malignant Pleural Mesothelioma. NCCN.
- European Society for Medical Oncology. (2024). ESMO Clinical Practice Guidelines: Mesothelioma. ESMO.
- USA Food and Drug Administration. (2024). FDA Approval History: Immunotherapy for Mesothelioma. FDA.
- World Health Organization. (2025). WHO Global Mesothelioma Registry Data. WHO.
- American Thoracic Society. (2024). ATS Clinical Practice Guideline: Management of Malignant Pleural Effusions. ATS.
- British Thoracic Society. (2024). BTS Guideline for Pleural Disease. BTS.
This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.
This Report Answers
- Estimating the size of the market and revenue from 2026 to 2036.
- Segmentation by Treatment, Route Of Administration, Technology, Disease Indication, End Users, Distribution Channel, and region.
- Insights about more than 30 markets across regions.
- Technology and treatment landscape analysis.
- Assessment of the competitive landscape.
- Finding investment opportunities across segments and regions.
- Supply chain and distribution analysis.
- Delivery of data in PDF and Excel formats.
Frequently Asked Questions
What is the global market demand for Pleural Diseases Therapeutics in 2026?
In 2026, the global Pleural Diseases Therapeutics Market is expected to be worth USD 6.00 billion.
How big will the Pleural Diseases Therapeutics Market be in 2036?
By 2036, the Pleural Diseases Therapeutics Market is expected to be worth USD 11.06 billion.
How much is demand expected to grow between 2026 and 2036?
Between 2026 and 2036, demand is expected to grow at a CAGR of 6.3%.
Which Treatment segment is expected to lead in 2026?
Chemotherapy is expected to account for 58.2% of the Treatment segment in 2026.
What is driving demand in USA?
USA is projected to grow at 6.4% through 2036, supported by the largest oncology pharmaceutical market and mesothelioma treatment infrastructure.
What is driving demand in South Korea?
South Korea is projected to grow at 6.4% through 2036, supported by oncology treatment investment and clinical research participation.
What does this report mean by 'Pleural Diseases Therapeutics Market definition'?
The Pleural Diseases Therapeutics Market covers pharmaceutical therapies (chemotherapy, immunotherapy, antibiotics, analgesics), surgical procedures (VATS, pleurodesis, thoracentesis), and medical devices (pleural catheters, drainage systems) for the treatment of malignant and non-malignant pleural conditions.
How does FMI forecast and validate the data?
Forecasting models use a hybrid bottom-up and top-down approach, starting with verified data and cross-checking against industry production data, regulatory databases, and manufacturer disclosures.
What is the global market demand for Pleural Diseases Therapeutics in 2026?
In 2026, the global Pleural Diseases Therapeutics Market is expected to be worth USD 6.00 billion.
How big will the Pleural Diseases Therapeutics Market be in 2036?
By 2036, the Pleural Diseases Therapeutics Market is expected to be worth USD 11.06 billion.
How much is demand expected to grow between 2026 and 2036?
Between 2026 and 2036, demand is expected to grow at a CAGR of 6.3%.
Which Treatment segment is expected to lead in 2026?
Chemotherapy is expected to account for 58.2% of the Treatment segment in 2026.
What is driving demand in USA?
USA is projected to grow at 6.4% through 2036, supported by the largest oncology pharmaceutical market and mesothelioma treatment infrastructure.
What is driving demand in South Korea?
South Korea is projected to grow at 6.4% through 2036, supported by oncology treatment investment and clinical research participation.
What does this report mean by 'Pleural Diseases Therapeutics Market definition'?
The Pleural Diseases Therapeutics Market covers pharmaceutical therapies (chemotherapy, immunotherapy, antibiotics, analgesics), surgical procedures (VATS, pleurodesis, thoracentesis), and medical devices (pleural catheters, drainage systems) for the treatment of malignant and non-malignant pleural conditions.
How does FMI forecast and validate the data?
Forecasting models use a hybrid bottom-up and top-down approach, starting with verified data and cross-checking against industry production data, regulatory databases, and manufacturer disclosures.
Preview the report firsthand - request a free sample
Get SampleGet the brochure for pricing and purchase details.
Get PDFTable of Content
- Executive Summary
- Global Market Outlook
- Demand-side Trends
- Supply-side Trends
- Technology Roadmap Analysis
- Analysis and Recommendations
- Market Overview
- Market Coverage / Taxonomy
- Market Definition / Scope / Limitations
- Research Methodology
- Chapter Orientation
- Analytical Lens and Working Hypotheses
- Market Structure, Signals, and Trend Drivers
- Benchmarking and Cross-market Comparability
- Market Sizing, Forecasting, and Opportunity Mapping
- Research Design and Evidence Framework
- Desk Research Programme (Secondary Evidence)
- Company Annual and Sustainability Reports
- Peer-reviewed Journals and Academic Literature
- Corporate Websites, Product Literature, and Technical Notes
- Earnings Decks and Investor Briefings
- Statutory Filings and Regulatory Disclosures
- Technical White Papers and Standards Notes
- Trade Journals, Industry Magazines, and Analyst Briefs
- Conference Proceedings, Webinars, and Seminar Materials
- Government Statistics Portals and Public Data Releases
- Press Releases and Reputable Media Coverage
- Specialist Newsletters and Curated Briefings
- Sector Databases and Reference Repositories
- FMI Internal Proprietary Databases and Historical Market Datasets
- Subscription Datasets and Paid Sources
- Social Channels, Communities, and Digital Listening Inputs
- Additional Desk Sources
- Expert Input and Fieldwork (Primary Evidence)
- Primary Modes
- Qualitative Interviews and Expert Elicitation
- Quantitative Surveys and Structured Data Capture
- Blended Approach
- Why Primary Evidence is Used
- Field Techniques
- Interviews
- Surveys
- Focus Groups
- Observational and In-context Research
- Social and Community Interactions
- Stakeholder Universe Engaged
- C-suite Leaders
- Board Members
- Presidents and Vice Presidents
- R&D and Innovation Heads
- Technical Specialists
- Domain Subject-matter Experts
- Scientists
- Physicians and Other Healthcare Professionals
- Governance, Ethics, and Data Stewardship
- Research Ethics
- Data Integrity and Handling
- Primary Modes
- Tooling, Models, and Reference Databases
- Desk Research Programme (Secondary Evidence)
- Data Engineering and Model Build
- Data Acquisition and Ingestion
- Cleaning, Normalisation, and Verification
- Synthesis, Triangulation, and Analysis
- Quality Assurance and Audit Trail
- Market Background
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Trends
- Scenario Forecast
- Demand in Optimistic Scenario
- Demand in Likely Scenario
- Demand in Conservative Scenario
- Opportunity Map Analysis
- Product Life Cycle Analysis
- Supply Chain Analysis
- Investment Feasibility Matrix
- Value Chain Analysis
- PESTLE and Porter’s Analysis
- Regulatory Landscape
- Regional Parent Market Outlook
- Production and Consumption Statistics
- Import and Export Statistics
- Market Dynamics
- Global Market Analysis 2021 to 2025 and Forecast, 2026 to 2036
- Historical Market Size Value (USD Million) Analysis, 2021 to 2025
- Current and Future Market Size Value (USD Million) Projections, 2026 to 2036
- Y-o-Y Growth Trend Analysis
- Absolute $ Opportunity Analysis
- Global Market Pricing Analysis 2021 to 2025 and Forecast 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Treatment
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Treatment , 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Treatment , 2026 to 2036
- Chemotherapy
- Systemic Chemotherapy
- Combination Chemotherapy
- Drug Class
- Antibiotics
- Antifungals
- Corticosteroids
- Narcotic Analgesics
- Nonsteroidal Anti-Inflammatory Drugs
- Bullectomy
- Surgical Lung Volume Reduction
- Video-Assisted Thoracoscopic Surgery
- Minimally Invasive Thoracic Surgery
- PleurX Catheter
- Indwelling Pleural Catheter
- Pleurodesis Therapy
- Chemical Pleurodesis
- Radiation Therapy
- External Beam Radiation
- Thoracentesis
- Fluid Drainage Procedure
- Thoracostomy
- Chest Tube Placement
- Chemotherapy
- Y-o-Y Growth Trend Analysis By Treatment , 2021 to 2025
- Absolute $ Opportunity Analysis By Treatment , 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Route Of Administration
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Route Of Administration, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Route Of Administration, 2026 to 2036
- Injectable
- Intravenous Administration
- Subcutaneous Injection
- Oral
- Tablets and Capsules
- Intrapleural
- Direct Pleural Administration
- Injectable
- Y-o-Y Growth Trend Analysis By Route Of Administration, 2021 to 2025
- Absolute $ Opportunity Analysis By Route Of Administration, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Technology
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Technology, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Technology, 2026 to 2036
- Conventional Therapies
- Pharmacological Therapy
- Surgical Procedures
- Targeted Therapies
- Biologics
- Immuno Oncology Therapies
- Conventional Therapies
- Y-o-Y Growth Trend Analysis By Technology, 2021 to 2025
- Absolute $ Opportunity Analysis By Technology, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Disease Indication
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Disease Indication, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Disease Indication, 2026 to 2036
- Malignant Pleural Diseases
- Pleural Effusion
- Mesothelioma
- Non Malignant Pleural Diseases
- Pleurisy
- Pneumothorax
- Malignant Pleural Diseases
- Y-o-Y Growth Trend Analysis By Disease Indication, 2021 to 2025
- Absolute $ Opportunity Analysis By Disease Indication, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By End Users
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By End Users, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By End Users, 2026 to 2036
- Hospitals
- Inpatient Care
- Surgical Value (USD Million)s
- Specialty Clinics
- Pulmonology Clinics
- Others
- Hospitals
- Y-o-Y Growth Trend Analysis By End Users, 2021 to 2025
- Absolute $ Opportunity Analysis By End Users, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Distribution Channel
- Introduction / Key Findings
- Historical Market Size Value (USD Million) Analysis By Distribution Channel, 2021 to 2025
- Current and Future Market Size Value (USD Million) Analysis and Forecast By Distribution Channel, 2026 to 2036
- Hospital Pharmacies
- Inpatient Pharmacy Services
- Outpatient Pharmacy Services
- Retail Pharmacies
- Chain Pharmacies
- Online Pharmacies
- E-Commerce Platforms
- Hospital Pharmacies
- Y-o-Y Growth Trend Analysis By Distribution Channel, 2021 to 2025
- Absolute $ Opportunity Analysis By Distribution Channel, 2026 to 2036
- Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Region
- Introduction
- Historical Market Size Value (USD Million) Analysis By Region, 2021 to 2025
- Current Market Size Value (USD Million) Analysis and Forecast By Region, 2026 to 2036
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia and Pacific
- Middle East & Africa
- Market Attractiveness Analysis By Region
- North America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- USA
- Canada
- Mexico
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- By Country
- Market Attractiveness Analysis
- By Country
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Key Takeaways
- Latin America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Brazil
- Chile
- Rest of Latin America
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- By Country
- Market Attractiveness Analysis
- By Country
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Key Takeaways
- Western Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Germany
- UK
- Italy
- Spain
- France
- Nordic
- BENELUX
- Rest of Western Europe
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- By Country
- Market Attractiveness Analysis
- By Country
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Key Takeaways
- Eastern Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Russia
- Poland
- Hungary
- Balkan & Baltic
- Rest of Eastern Europe
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- By Country
- Market Attractiveness Analysis
- By Country
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Key Takeaways
- East Asia Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- China
- Japan
- South Korea
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- By Country
- Market Attractiveness Analysis
- By Country
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Key Takeaways
- South Asia and Pacific Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- India
- ASEAN
- Australia & New Zealand
- Rest of South Asia and Pacific
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- By Country
- Market Attractiveness Analysis
- By Country
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Key Takeaways
- Middle East & Africa Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
- Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
- Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
- By Country
- Kingdom of Saudi Arabia
- Other GCC Countries
- Turkiye
- South Africa
- Other African Union
- Rest of Middle East & Africa
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- By Country
- Market Attractiveness Analysis
- By Country
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Key Takeaways
- Key Countries Market Analysis
- USA
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Canada
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Mexico
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Brazil
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Chile
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Germany
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- UK
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Italy
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Spain
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- France
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- India
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- ASEAN
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Australia & New Zealand
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- China
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Japan
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- South Korea
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Russia
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Poland
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Hungary
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Kingdom of Saudi Arabia
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Turkiye
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- South Africa
- Pricing Analysis
- Market Share Analysis, 2025
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- USA
- Market Structure Analysis
- Competition Dashboard
- Competition Benchmarking
- Market Share Analysis of Top Players
- By Regional
- By Treatment
- By Route Of Administration
- By Technology
- By Disease Indication
- By End Users
- By Distribution Channel
- Competition Analysis
- Competition Deep Dive
- AstraZeneca plc
- Overview
- Product Portfolio
- Profitability by Market Segments (Product/Age /Sales Channel/Region)
- Sales Footprint
- Strategy Overview
- Marketing Strategy
- Product Strategy
- Channel Strategy
- Bristol-Myers Squibb
- Becton, Dickinson and Company
- Roche Holding AG (Genentech)
- Rocket Medical plc
- Novocure
- Smiths Medical
- Veracyte, Inc.
- Medtronic
- BioInvent International
- AstraZeneca plc
- Competition Deep Dive
- Assumptions & Acronyms Used
